Importer of Controlled Substances; Notice of Application, 3641-3642 [E9-1051]
Download as PDF
<![CDATA[
mstockstill on PROD1PC66 with NOTICES
Federal Register / Vol. 74, No. 12 / Wednesday, January 21, 2009 / Notices
under specified circumstances.
Specifically, Sound Technology (S.Z.)
Co. Ltd., Shenzhen, PEOPLE’S
REPUBLIC OF CHINA; Vulcan Inc.,
Seattle, WA; Yusan Industries, Ltd.,
Hong Kong, HONG KONG-CHINA; and
Zentek Technology Japan, Inc., Tokyo,
JAPAN have been added as parties to
this venture.
Also, AWIND, Inc., Taipei, TAIWAN;
Bestguide Group Limited, Kowloon,
HONG KONG-CHINA; Clevo Co.,
Taipei, TAIWAN; Coretronic
Corporation, Miao-Li, TAIWAN; Cosmic
Digital Technology, Ltd., Hong Kong,
HONG KONG-CHINA; Daewoo
Electronics Corporation, Seoul,
REPUBLIC OF KOREA; Dahaam E-Tec
Co., Seoul, REPUBLIC OF KOREA;
Disctronics Texas, Inc. dba DiscUSA,
Plano, TX; Ever Best Industrial (H.K.)
Limited, Kowloon, HONG KONGCHINA; Giant Video Electronics Co.,
Ltd., Yueh Long, HONG KONG-CHINA;
Hansong (Nanjing) Electronic Ltd.,
Nanjing, PEOPLE’S REPUBLIC OF
CHINA; Hing Lung Technology (HK)
Company Limited, Hong Kong, HONG
KONG-CHINA; KRCD India PVT Ltd.,
Mumbai, INDIA; Leadtek Research, Inc.,
Taipei, TAIWAN; Link Concept
Technology Ltd., Kowloon, HONG
KONG-CHINA; Linpus Technologies,
Inc., Taipei, TAIWAN; Major Digital
Technology Co., Ltd., Jiangxi, PEOPLE’S
REPUBLIC OF CHINA; ODS Optical
Disc Service GmbH, Dassow,
GERMANY; Premium Disc Corp.,
Mississauga, Ontario, CANADA;
Princeton Technology Corp., Taipei,
TAIWAN; Prof ilo Telra Elektronic San.
Ve Tic. A.S., Istanbul, TURKEY; SKC
Co. Ltd., Seoul, REPUBLIC OF KOREA;
Zhongshan Dingcai AV Technology
Ltd., Zhongshan, PEOPLE’S REPUBLIC
OF CHINA; and Ziova Corporation Pty
Ltd., Lonsdale, South Australia,
AUSTRALIA have withdrawn as parties
to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and DVD CCA
intends to file additional written
notifications disclosing all changes in
membership.
On April 11, 2001, DVD CCA filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on August 3, 2001 (66 FR 40727).
The last notification was filed with
the Department on September 10, 2008.
A notice was published in the Federal
VerDate Nov<24>2008
18:54 Jan 16, 2009
Jkt 217001
3641
Register pursuant to Section 6(b) of the
Act on October 21, 2008 (73 FR 62541)
DEPARTMENT OF JUSTICE
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. E9–757 Filed 1–16–09; 8:45 am]
Importer of Controlled Substances;
Notice of Application
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Wireless Industrial
Technology Konsortium Inc.
Notice is hereby given that, on
December 2, 2008, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’)
Wireless Industrial Technology
Konsortium Inc. (‘‘WITK’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
Softing AG, Haar, GERMANY; and
Cooper Industries, Houston, TX have
been added as parties to this venture.
Also, Airsprite Technologies, Inc.,
Marlborough, MA has withdrawn as a
party to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and WITK intends
to file additional written notifications
disclosing all changes in membership.
On August 8, 2008, WITK filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on September 18, 2008 (73 FR
54170).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. E9–758 Filed 1–16–09; 8:45 am]
BILLING CODE 4410–11–M
PO 00000
Frm 00101
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
November 26, 2008, Kenco VPI,
Division of Kenco Group, Inc., 350
Corporate Place, Chattanooga,
Tennessee 37419, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Nabilone (7379), a basic
class of controlled substance listed in
schedule II.
The company plans to import the
listed controlled substance for
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than February 20, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975 (40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
E:\FR\FM\21JAN1.SGM
21JAN1
3642
Federal Register / Vol. 74, No. 12 / Wednesday, January 21, 2009 / Notices
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–1051 Filed 1–16–09; 8:45 am]
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on PROD1PC66 with NOTICES
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations
§ 1301.34(a), this is notice that on
October 23, 2008, Noramco Inc., 1440
Olympic Drive, Athens, Georgia 30601,
has made letter to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic class Thebaine
(9333), a controlled substance listed in
schedule II.
The company plans to import
analytical reference standards for
distribution to its customers for research
purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43,
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and
must be filed no later than February 20,
2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
§ 1301.34(b), (c), (d), (e), and (f). As
noted in a previous notice published in
the Federal Register on September 23,
1975, (40 FR 43745–46), all applicants
for registration to import the basic class
of any controlled substances in schedule
VerDate Nov<24>2008
18:54 Jan 16, 2009
Jkt 217001
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–1052 Filed 1–16–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on
September 4, 2008, Medical Isotopes
Inc., 100 Bridge Street, Pelham, New
Hampshire 03076, made application to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Etorphine HCL (9059) ..................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium, powdered (9639) .............
Levo-alphacetylmethadol (9648) ..
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Drug
Oxymorphone (9652) ...................
Fentanyl (9801) ............................
Schedule
II
II
The company plans to import small
quantities of the listed controlled
substances as reference standards for
distribution for research and analytical
purposes only.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, Virginia 22152; and
must be filed no later than February 20,
2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic class of
any controlled substances in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–1055 Filed 1–16–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 5, 2008,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
E:\FR\FM\21JAN1.SGM
21JAN1
]]>Agencies
[Federal Register Volume 74, Number 12 (Wednesday, January 21, 2009)]
[Notices]
[Pages 3641-3642]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-1051]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on November 26, 2008, Kenco VPI,
Division of Kenco Group, Inc., 350 Corporate Place, Chattanooga,
Tennessee 37419, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as an importer of Nabilone
(7379), a basic class of controlled substance listed in schedule II.
The company plans to import the listed controlled substance for
distribution to its customers.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than February 20, 2009.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR Sec. 1301.34(b),
(c), (d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975 (40 FR 43745), all applicants
for registration to import a basic class of any controlled substance in
schedule I or II are, and will continue to be, required to demonstrate
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR
1301.34(b), (c), (d), (e), and (f) are satisfied.
[[Page 3642]]
Dated: January 9, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-1051 Filed 1-16-09; 8:45 am]
BILLING CODE 4410-09-P
